Milestones/updates due by YE should rally SGMO, provided they deliver the goods.
Fabry first patient dosed
SB-525 data at ASH
beta thal prelim data (venue?)
TX-200 CTA
The Q3 ER/CC could be where we get a substantive update on the Fabry program, including patient dosing schedule, and update on TX-200. After the Q3 CC, ASH will provide the big spotlight for the hemo A program, especially given Biomarin appears to be holding off on their Valrox data release until mid-2020. All eyes will be on SB-525 and what Pfizer plans to do with it. At this share price upside is greater, than downside imo.